中国医学创新2024，Vol.21Issue(16)：128-131,4.DOI:10.3969/j.issn.1674-4985.2024.16.028
拉氧头孢钠联合前列地尔治疗急性附睾炎的临床效果及安全性
Clinical Efficacy and Safety of Latamoxef Sodium Combined with Alprostadil in the Treatment of Acute Epididymitis
林辉煌 1董自强1
作者信息
- 1. 三峡大学附属第一临床医学院(宜昌市中心人民医院)泌尿外科 湖北 宜昌 443000
- 折叠
摘要
Abstract
Objective:To investigate the clinical effect and safety of Latamoxef Sodium combined with Alprostadil in the treatment of acute epididymitis.Method:A total of 90 patients with acute epididymitis treated in the First Clinical Medical College Affiliated to China Three Gorges University from August 2021 to September 2023 were selected and divided according to the random number table method,of which 45 were included in the conventional treatment group(Latamoxef Sodium)and 45 were included in the combined treatment group(Alprostadil+Latamoxef Sodium).The Barthel index score,epididymis volume,fever remission time,urinary tract infection(UTI)remission time,total effective rate and incidence of adverse reactions were analyzed in the two groups.Result:Before treatment,there were no significant differences in Barthel index score and epididymal volume between the two groups(P>0.05);the Barthel index score of the combined treatment group was significantly higher than that of the conventional treatment group,and the epididymal volume was significantly lower than that of the conventional treatment group(P<0.05).Compared with the conventional treatment group,the time of fever reduction and UTI remission in the combined treatment group were significantly earlier,the total effective rate of treatment was higher,and the incidence of adverse reactions after medication was lower(P<0.05).Conclusion:In the treatment of patients with acute epididymitis,the total effective rate and quality of life of patients can be effectively improved by the combination of Latamoxef Sodium and Alprostadil,and the incidence of adverse reactions is low.关键词
拉氧头孢钠/前列地尔/急性附睾炎Key words
Latamoxef Sodium/Alprostadil/Acute epididymitis引用本文复制引用
林辉煌,董自强..拉氧头孢钠联合前列地尔治疗急性附睾炎的临床效果及安全性[J].中国医学创新,2024,21(16):128-131,4.
